Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,210 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Arm Clear all
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
View directory record Official record
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 4 Interventional

Opiate-Induced Tolerance & Hyperalgesia in Pain Patients

NCT00246532
View directory record Official record
Conditions
Chronic Low Back Pain, Opioid-induced Hyperalgesia
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 3, 2026, 10:27 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Oxytocin and Approach-avoid in Grief

NCT04505904
View directory record Official record
Conditions
Prolonged Grief Disorder, Bereavement
Interventions
Syntocinon, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Ruxolitinib for Premalignant Breast Disease

NCT02928978
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

NCT07022678
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Best Practice, Biospecimen Collection, Cytarabine, Electronic Health Record Review, Placebo Administration, Xylitol-containing Oral Wipe
Other · Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 25 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
36
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Madera, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Withdrawn Not applicable Interventional

Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)

NCT00890643
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 3, 2026, 10:27 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery

NCT03241485
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 3, 2026, 10:27 AM EDT
Not listed Not applicable Interventional

Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders

NCT06502717
View directory record Official record
Conditions
Mental Health Issue, Depression, Anxiety
Interventions
VIOME Precision Nutrition Program
Combination Product
Lead sponsor
Viome
Industry
Eligibility
25 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H3N2 M2SR in Pediatric Population

NCT03553940
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

NCT02334306
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
AMG 557/MEDI5872, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
San Francisco, California • Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 3, 2026, 10:27 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Daily Glucomannan in Overweight Patients

NCT01485718
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Glucomannan, Placebo
Dietary Supplement
Lead sponsor
ProMedica Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 3, 2026, 10:27 AM EDT
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 3, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
86
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NCT00803543
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 3, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 3, 2026, 10:27 AM EDT